RedHill Biopharma (RDHL) Intangibles (2022 - 2024)
RedHill Biopharma (RDHL) has disclosed Intangibles for 3 consecutive years, with $5.5 million as the latest value for Q4 2024.
- Quarterly Intangibles fell 0.56% to $5.5 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2024, down 0.56% year-over-year, with the annual reading at $5.5 million for FY2024, 0.56% down from the prior year.
- Intangibles for Q4 2024 was $5.5 million at RedHill Biopharma, down from $5.6 million in the prior quarter.
- The five-year high for Intangibles was $89.4 million in Q4 2022, with the low at $5.5 million in Q4 2024.
- Average Intangibles over 3 years is $33.5 million, with a median of $5.6 million recorded in 2023.
- The sharpest move saw Intangibles plummeted 93.76% in 2023, then fell 0.56% in 2024.
- Over 3 years, Intangibles stood at $89.4 million in 2022, then tumbled by 93.76% to $5.6 million in 2023, then decreased by 0.56% to $5.5 million in 2024.
- According to Business Quant data, Intangibles over the past three periods came in at $5.5 million, $5.6 million, and $89.4 million for Q4 2024, Q4 2023, and Q4 2022 respectively.